NasdaqGS:KRYSBiotechs
A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Driven Earnings Beat And Pipeline Progress
Krystal Biotech (KRYS) shares moved after the company reported first quarter 2026 results, with earnings per share above estimates and revenue growth tied to strong Vyjuvek uptake, and reaffirmed expense guidance.
See our latest analysis for Krystal Biotech.
The stock has built solid momentum over the past year, with a 1-year total shareholder return of 128.6% and a year to date share price return of 22.24%. The latest 1-day move of 2.94% after earnings suggests investors are reassessing...